{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:53:57Z","timestamp":1771030437679,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4335-4","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T13:33:09Z","timestamp":1523626389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy"],"prefix":"10.1186","volume":"18","author":[{"given":"Mathieu","family":"Gauth\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Richard-Molard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eug\u00e9nie","family":"Rigault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Buecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Bellet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wulfran","family":"Cacheux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Li\u00e8vre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"4335_CR1","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","volume":"299","author":"JA Ajani","year":"2008","unstructured":"Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914\u201321.","journal-title":"JAMA"},{"key":"4335_CR2","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1002\/cncr.25188","volume":"116","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116:4007\u201313.","journal-title":"Cancer"},{"key":"4335_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.clinbiochem.2004.05.009","volume":"37","author":"V Barak","year":"2004","unstructured":"Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004;37:529\u201340.","journal-title":"Clin Biochem"},{"key":"4335_CR4","first-page":"5519","volume":"35","author":"V Barak","year":"2015","unstructured":"Barak V, Meirovitz A, Leibovici V, Rachmut J, Peretz T, Eliashar R, Gross M. The diagnostic and prognostic value of tumor markers (CEA, SCC, CYFRA 21-1, TPS) in head and neck cancer patients. Anticancer Res. 2015;35:5519\u201324.","journal-title":"Anticancer Res"},{"key":"4335_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jso.23283","volume":"107","author":"JHS Correa","year":"2013","unstructured":"Correa JHS, Castro LS, Kesley R, Dias JA, Jesus JP, Olivatto LO, Martins IO, Lopasso FP. Salvage abdominoperineal resection for anal cancer following chemoradiation: a proposed scoring system for predicting postoperative survival. J Surg Oncol. 2013;107:486\u201392.","journal-title":"J Surg Oncol"},{"key":"4335_CR6","first-page":"165","volume-title":"AJCC Cancer staging manual","author":"S Edge","year":"2010","unstructured":"Edge S, Byrd D, Compton CC, Fritz A, Greene F, Trotti A. Anus. In: AJCC Cancer staging manual. New York: Springer; 2010. p. 165\u201373."},{"key":"4335_CR7","first-page":"298","volume":"40","author":"L Giovanella","year":"2002","unstructured":"Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clin Chem Lab Med. 2002;40:298\u2013303.","journal-title":"Clin Chem Lab Med"},{"key":"4335_CR8","first-page":"275","volume":"82","author":"M Indinnimeo","year":"1997","unstructured":"Indinnimeo M, Reale MG, Cicchini C, Stazi A, Fiori E, Izzo P. CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors. Int Surg. 1997;82:275\u20139.","journal-title":"Int Surg"},{"key":"4335_CR9","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.4238\/2015.April.27.6","volume":"14","author":"LI Kuang","year":"2015","unstructured":"Kuang LI, Song WJ, Qing HM, Yan S, Song FL. CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis. Genet Mol Res. 2015;14:3921\u201331.","journal-title":"Genet Mol Res"},{"key":"4335_CR10","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s10350-008-9361-x","volume":"51","author":"P Mariani","year":"2008","unstructured":"Mariani P, Ghanneme A, De la Rochefordi\u00e8re A, Girodet J, Falcou MC, Salmon RJ. Abdominoperineal resection for anal cancer. Dis Colon Rectum. 2008;51:1495\u2013501.","journal-title":"Dis Colon Rectum"},{"key":"4335_CR11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0360-3016(00)01518-2","volume":"49","author":"SE Mitchell","year":"2001","unstructured":"Mitchell SE, Mendenhall WM, Zlotecki RA, Carroll RR. Squamous cell carcinoma of the anal canal. Int J Radiat Oncol. 2001;49:1007\u201313.","journal-title":"Int J Radiat Oncol"},{"key":"4335_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000217908","volume":"15","author":"R Molina","year":"1994","unstructured":"Molina R, Agusti C, Filella X, Jo J, Joseph J, Gim\u00e9nez N, Ballesta AM. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumour Biol. 1994a;15:318\u201325.","journal-title":"Tumour Biol"},{"key":"4335_CR13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/172460089400900206","volume":"9","author":"R Molina","year":"1994","unstructured":"Molina R, Agusti C, Ma\u00f1e JM, Filella X, Jo J, Joseph J, Gim\u00e9nez N, Estap\u00e9 J, Ballesta AM. CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers. 1994b;9:96\u2013101.","journal-title":"Int J Biol Markers"},{"key":"4335_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","volume":"49","author":"L Moureau-Zabotto","year":"2017","unstructured":"Moureau-Zabotto L, Vendrely V, Abramowitz L, Borg C, Francois E, Goere D, Huguet F, Peiffert D, Siproudhis L, Ducreux M, Bouch\u00e9 O. Anal cancer: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Dig Liver Dis. 2017;49:831\u201340.","journal-title":"Dig Liver Dis"},{"key":"4335_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/dote\/11.1.35","volume":"11","author":"T Nakamura","year":"2017","unstructured":"Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus. 2017;11:35\u20139.","journal-title":"Dis Esophagus"},{"key":"4335_CR16","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/bjc.1996.288","volume":"73","author":"B Nakata","year":"1996","unstructured":"Nakata B, Chung YS, Kato Y, Ogawa M, Ogawa Y, Inui A, Maeda K, Sawada T, Sowa M. Clinical significance of serum CYFRA 21-1 in gastric cancer. Br J Cancer. 1996;73:1529\u201332.","journal-title":"Br J Cancer"},{"key":"4335_CR17","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/1097-0142(20000915)89:6<1285::AID-CNCR13>3.0.CO;2-G","volume":"89","author":"B Nakata","year":"2000","unstructured":"Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H, Hirakawa K. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer. 2000;89:1285\u201390.","journal-title":"Cancer"},{"key":"4335_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/sj.bjc.6602074","volume":"91","author":"B Nakata","year":"2004","unstructured":"Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer. 2004;91:873\u20138.","journal-title":"Br J Cancer"},{"key":"4335_CR19","volume-title":"Surveillance, epidemiology, and end results program. SEER stat fact sheets: anal Cancer","author":"National Cancer Institute","year":"2016","unstructured":"National Cancer Institute (2016) Surveillance, epidemiology, and end results program. SEER stat fact sheets: anal Cancer. \n                    http:\/\/seer.cancer.gov\/statfacts\/html\/anus.html\n                    \n                   (accessed: 01 Dec 2017)."},{"key":"4335_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ygyno.2015.04.012","volume":"138","author":"X Piao","year":"2015","unstructured":"Piao X, Kong T-W, Chang S-J, Paek J, Chun M, Ryu H-S. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases. Gynecol Oncol. 2015;138:89\u201393.","journal-title":"Gynecol Oncol"},{"key":"4335_CR21","first-page":"61","volume":"53","author":"JL Pujol","year":"1993","unstructured":"Pujol JL, Grenier J, Daur\u00e8s JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993;53:61\u20136.","journal-title":"Cancer Res"},{"key":"4335_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1056\/NEJM200003163421107","volume":"342","author":"DP Ryan","year":"2000","unstructured":"Ryan DP, Compton CC, Mayer RJ. Carcinoma of the Anal Canal. N Engl J Med. 2000;342:792\u2013800.","journal-title":"N Engl J Med"},{"key":"4335_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0360-3016(94)90221-6","volume":"29","author":"J-P Wagner","year":"1994","unstructured":"Wagner J-P, Mahe MA, Romestaing P, Rocher FP, Berger C, Trillet-Lenoir V, Gerard J-P. Radiation therapy in the conservative treatment of carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 1994;29:17\u201323.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4335_CR24","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.5301\/jbm.5000177","volume":"31","author":"L Wang","year":"2016","unstructured":"Wang L, Wang D, Zheng G, Yang Y, Du L, Dong Z, Zhang X, Wang C. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. Int J Biol Markers. 2016;31:e80\u20137.","journal-title":"Int J Biol Markers"},{"key":"4335_CR25","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1002\/cncr.28055","volume":"119","author":"M Williams","year":"2013","unstructured":"Williams M, Swampillai A, Osborne M, Mawdsley S, Hughes R, Harrison M, Harvey R, Glynne-Jones R, Mount Vernon Colorectal Cancer Network. Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin. Cancer. 2013;119:2391\u20138.","journal-title":"Cancer"},{"key":"4335_CR26","first-page":"3381","volume":"9","author":"C Yuan","year":"2016","unstructured":"Yuan C, Yang K, Tang H, Chen D. Diagnostic values of serum tumor markers Cyfra 21-1, SCC ag, ferritin, CEA, CA 19-9, and AFP in oral\/oropharyngeal squamous cell carcinoma. OncoTargets Ther. 2016;9:3381\u20136.","journal-title":"OncoTargets Ther"},{"key":"4335_CR27","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/cam4.493","volume":"4","author":"Z-H Zhang","year":"2015","unstructured":"Zhang Z-H, Han Y-W, Liang H, Wang L-M. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer. Cancer Med. 2015;4:1633\u20138.","journal-title":"Cancer Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4335-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T23:10:54Z","timestamp":1555110654000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4335-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4335"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4335-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,13]]},"assertion":[{"value":"19 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was reviewed and approved by the Ethics Committee of the Institut Curie (No. A10\u2013024). According to French regulations, patients were informed of research performed with the biological specimens obtained during their treatment and did not express opposition.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"417"}}